Visa and Mastercard have agreed to a revised settlement with merchants who accused the payment giants of imposing excessive fees for processing credit card transactions. The proposed deal, revealed in a court filing on Monday in Brooklyn federal court, represents the latest chapter in a long-standing antitrust dispute between the card networks and millions of U.S. retailers.
The case stems from claims that Visa and Mastercard violated antitrust laws by colluding to maintain high interchange fees—charges paid by merchants to banks each time customers use credit cards. Retailers argued that these fees unfairly increased their operating costs, leading to higher prices for consumers. The latest agreement follows earlier settlement efforts that faced legal challenges and rejections from some merchant groups seeking stronger terms.
While details of the revised settlement have not yet been publicly disclosed, legal experts say it could involve changes to fee structures, greater transparency, or new options for merchants to steer customers toward lower-cost payment methods. The settlement aims to resolve years of litigation that have cost both sides billions in legal expenses and strained relationships between retailers and card networks.
Visa and Mastercard, which together process the majority of global credit card transactions, have consistently denied wrongdoing but expressed interest in resolving the matter to provide certainty for their partners. The court will review the proposal to determine whether it meets fairness standards and benefits the merchant community.
If approved, the settlement could mark a turning point in the ongoing debate over credit card fees, potentially setting a precedent for future regulation in the payments industry. As digital transactions continue to rise, both merchants and consumers are watching closely to see how this agreement might reshape the cost of doing business in an increasingly cashless economy.


CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Supreme Court Signals Doubts Over Trump’s Bid to Fire Fed Governor Lisa Cook
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations
New York Judge Orders Redrawing of GOP-Held Congressional District
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Trump Administration Appeals Judge’s Order Limiting ICE Tactics in Minneapolis
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 



